 Connection
Lisa Maier to Prospective Studies
This is a "connection" page, showing publications Lisa Maier has written about Prospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.061 |
|
|
|
-
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. Nat Commun. 2025 Nov 18; 16(1):10111.
Score: 0.024
-
Strykowski R, Patel DC, Neto MR, Hena KM, Gulati M, Maier LA, Patterson K. Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study. BMJ Open Respir Res. 2022 07; 9(1).
Score: 0.019
-
Baughman RP, Judson MA, Beaumont JL, Maier LA, Sweiss NJ, Culver DA, Chen ES, Singh N, Lower EE, Reeves R, Hamzeh N, Grutters JC, Valeyre D, Birring SS. Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study. Ann Am Thorac Soc. 2021 03; 18(3):477-485.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|